Role of beta-defensin 2 and interleukin-4 receptor as stroke outcome biomarkers

Journal of Neurochemistry

Volumn 129, Issue 3, 2014, Pages 463-472

  García Berrocoso, Teresa ^a   Giralt, Dolors ^a   Bustamante, Alejandro ^a   Llombart, Victor ^a   Rubiera, Marta ^b   Penalba, Anna ^a   Boada, Cristina ^a   Espadaler, Marc ^a   Molina, Carlos ^b   Montaner, Joan ^a,b,c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

biomarkers; cerebral ischemia; immune response; outcome; prognosis; stroke

Indexed keywords

BIOMARKERS; CEREBRAL ISCHEMIA; IMMUNE RESPONSE; OUTCOME; PROGNOSIS; STROKE;

AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BETA-DEFENSINS; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; RECEPTORS, INTERLEUKIN-4; RECOVERY OF FUNCTION; ROC CURVE; SENSITIVITY AND SPECIFICITY; STROKE;

EID: 84899418643     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12649     Document Type: Article

References (47)

1. Alawneh J. A., Moustafa R. R., and, Baron J. C., (2009) Hemodynamic factors and perfusion abnormalities in early neurological deterioration. Stroke 40, e443-e450.
2. Arenillas J. F., Rovira A., Molina C. A., Grivé E., Montaner J., and, Alvarez-Sabín J., (2002) Prediction of early neurological deterioration using diffusion- and perfusion-weighted imaging in hyperacute middle cerebral artery ischemic stroke. Stroke 33, 2197-2203.
3. Barker P. E., Wagner P. D., Stein S. E., Bunk D. M., Srivastava S., and, Omenn G. S., (2006) Standards for plasma and serum proteomics in early cancer detection: a needs assessment report from the National Institute of Standards and Technology-National Cancer Institute Standards, methods, assays, reagents and technologies workshop, August 18-19, 2005. Clin. Chem. 52, 1669-1674.
4. Bath P. M. W., Blann A., Smith N., and, Butterworth R. J., (1998) Von Willebrand factor, P-selectin and fibrinogen levels in patients with acute ischaemic and haemorrhagic stroke, and their relationship with stroke sub-type and functional outcome. Platelets 9, 155-159.
5. Brott T., and, Bogousslavsky J., (2000) Treatment of acute ischemic stroke. N. Engl. J. Med. 343, 710-722.
6. Brott T. G., Haley E. C., Jr, Levy D. E., et al,. (1992) Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 23, 632-640.
7. De Marchis G. M., Katan M., Weck A., et al,. (2013) Copeptin adds prognostic information after ischemic stroke: results from the CoRisk study. Neurology 80, 1278-1286.
8. DeLong E. R., DeLong D. M., and, Clarke-Pearson D. L., (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44, 837-845.
9. Desilles J. P., Meseguer E., Labreuche J., et al,. (2013) Diabetes mellitus, admission glucose, and outcomes after stroke thrombolysis: A registry and systematic review. Stroke 44, 1915-1923.
10. Efstathiou S. P., Tsiakou A. G., Tsioulos D. I., Panagiotou T. N., Pefanis A. V., Achimastos A. D., and, Mountokalakis T. D., (2007) Prognostic significance of plasma resistin levels in patients with atherothrombotic ischemic stroke. Clin. Chim. Acta 378, 78-85.
11. Ernoult E., Bourreau A., Gamelin E., and, Guette C., (2010) A proteomic approach for plasma biomarker discovery with iTRAQ labelling and OFFGEL fractionation. J. Biomed. Biotechnol. 2010, 927917.
12. Fragnoud R., Yugueros-Marcos J., Pachot A., and, Bedin F., (2012) Isotope coded protein labeling analysis of plasma specimens from acute severe dengue fever patients. Proteome Sci. 10, 60.
13. Grube M. M., Koennecke H.-C., Walter G., Meisel A., Sobesky J., Nolte C. H., Wellwood I., and, Heuschmann P. U., (2013) Influence of acute complications on outcome 3 months after ischemic stroke. PLoS ONE 8, e75719.
14. Jickling G. C., and, Sharp F. R., (2011) Blood biomarkers of ischemic stroke. Neurotherapeutics 8, 349-360.
15. Jung T., Schrader N., Hellwig M., Enssle K. H., and, Neumann C., (1999a) Soluble human interleukin-4 receptor is produced by activated T cells under the control of metalloproteinases. Int. Arch. Allergy Immunol. 119, 23-30.
16. Jung T., Wagner K., Neumann C., and, Heusser C. H., (1999b) Enhancement of human IL-4 activity by soluble IL-4 receptors in vitro. Eur. J. Immunol. 29, 864-871.
17. Karp N. A., and, Lilley K. S., (2009) Investigating sample pooling strategies for DIGE experiments to address biological variability. Proteomics 9, 388-397.
18. Kendziorski C., Irizarry R. A., Chen K. S., Haaq J. D., and, Gould M. N., (2005) On the utility of pooling biological samples in microarray experiments. Proc. Natl Acad. Sci. USA 102, 4252-4257.
19. Lin L. C., Lee T. H., Chang C. H., et al,. (2012) Predictors of clinical deterioration during hospitalization following acute ischemic stroke. Eur. Neurol. 67, 186-192.
20. Liu K. X., Chen S. Q., Zhang H., Guo J. Y., Li Y. S., and, Huang W. Q., (2009) Intestinal ischaemia/reperfusion upregulates β-defensin-2 expression and causes acute lung injury in the rat. Injury 40, 950-955.
21. Mehta S. L., Manhas N., and, Raghubir R., (2007) Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res. Rev. 54, 34-66.
22. Mendioroz M., Fernández-Cadenas I., Alvarez-Sabín J., et al,. (2009) Endogenous activated protein C predicts hemorrhagic transformation and mortality after tissue plasminogen activator treatment in stroke patients. Cerebrovasc. Dis. 28, 143-150.
23. Mendioroz M., Fernández-Cadenas I., Rosell A., Delgado P., Domingues-Montanari S., Ribõ M., Penalba A., Quintana M., Alvarez-Sabín J., and, Montaner J., (2011) Osteopontin predicts long-term functional outcome among ischemic stroke patients. J. Neurol. 258, 486-493.
24. Montaner J., Alvarez-Sabín J., Molina C., Anglés A., Abilleira S., Arenillas J., González M. A., and, Monasterio J., (2001) Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 32, 1759-1766.
25. Montaner J., Fernandez-Cadenas I., Molina C. A., Ribõ M., Huertas R., Rosell A., Penalba A., Ortega L., Chacõn P., and, Alvarez-Sabín J., (2006) Poststroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis. Stroke 37, 1205-1210.
26. Montaner J., García-Berrocoso T., Mendioroz M., et al,. (2012) Brain natriuretic peptide is associated with worsening and mortality in acute stroke patients but adds no prognostic value to clinical predictors of outcome. Cerebrovasc. Dis. 34, 240-245.
27. Nickel D., Busch M., Mayer D., Hagemann B., Knoll V., and, Stenger S., (2012) Hypoxia triggers the expression of human β defensin 2 and antimicrobial activity against Mycobacterium tuberculosis in human macrophages. J. Immunol. 188, 4001-4007.
28. O'Neill P. A., Davies I., Fullerton K. J., and, Bennett D., (1991) Stress hormone and blood glucose response following acute stroke in the elderly. Stroke 22, 842-847.
29. Pencina M. J., D'Agostino R. B., D'Agostino R. B., and, Vasan R. S., (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat. Med. 27, 157-172.
30. Pepe M. S., Janes H., Longton G., Leisenring W., and, Newcomb P., (2004) Limitations of the Odds Ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am. J. Epidemiol. 159, 882-890.
31. Pickering J. W., and, Endre Z. H., (2012) New metrics for assessing diagnostic potential of candidate biomarkers. Clin. J. Am. Soc. Nephrol. 7, 1355-1364.
32. Roger V. L., Go A. S., Lloyd-Jones D. M., et al,. (2012) Heart disease and stroke statistics-2012 update: A report from the american heart association. Circulation 125, e2-e220.
33. Roquer J., Rodríguez-Campello A., Gomis M., et al,. (2008) Acute stroke unit care and early neurological deterioration in ischemic stroke. J. Neurol. 255, 1012-1017.
34. Schröder J. M., and, Harder J., (1999) Human beta-defensin-2. Int. J. Biochem. Cell Biol. 31, 645-651.
35. Sham P., Bader J. S., Craig I., O'Donovan M., and, Owen M., (2002) DNA pooling: a tool for large-scale association studies. Nat. Rev. Genet. 3, 862-871.
36. Smith C. J., Emsley H. C. A., Gavin C. M., et al,. (2004) Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol. 4, 2.
37. Tiszlavicz Z., Somogyvári F., Szolnoki Z., Sztriha L. K., Németh B., Vécsei L., and, Mándi Y., (2012) Genetic polymorphisms of human β-defensins in patients with ischemic stroke. Acta Neurol. Scand. 126, 109-115.
38. Vila N., Castillo J., Dávalos A., and, Chamorro A., (2000) Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 31, 2325-2329.
39. Walker L. C., Thompson B. A., Waddell N., and, kConFab Investigators, Grimmond S.M. and Spurdle A.B., (2010) Use of DNA-Damaging agents and RNA pooling to assess expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients. PLoS Genet. 6, e1000850.
40. Welsh P., Barber M., Langhorne P., Rumley A., Lowe G. D., and, Stott D. J., (2009) Associations of inflammatory and haemostatic biomarkers with poor outcome in acute ischaemic stroke. Cerebrovasc. Dis. 27, 247-253.
41. Whiteley W., Chong W. L., Sengupta A., and, Sandercock P., (2009) Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke 40, e380-e389.
42. Whiteley W., Wardlaw J., Dennis M., Lowe G., Rumley A., Sattar N., Welsh P., Green A., Andrews M., and, Sandercock P., (2012) The use of blood biomarkers to predict poor outcome after acute transient ischemic attack or ischemic stroke. Stroke 43, 86-91.
43. Worthmann H., Tryc A. B., Goldbecker A., Ma Y. T., Tountopoulou A., Hahn A., Dengler R., Lichtinghagen R., and, Weissenborn K., (2010) The temporal profile of inflammatory markers and mediators in blood after acute ischemic stroke differs depending on stroke outcome. Cerebrovasc. Dis. 30, 85-92.
44. Zaremba J., Ilkowski J., and, Losy J., (2006) Serial measurements of levels of the chemokines CCL2, CCL3 and CCL5 in serum of patients with acute ischemic stroke. Folia Neuropathol. 44, 282-289.
45. Zeng L., Liu J., Wang Y., Wang L., Weng S., Chen S., and, Yang G. Y., (2013) Cocktail blood biomarkers: prediction of clinical outcomes in patients with acute ischemic stroke. Eur. Neurol. 69, 68-75.
46. Zhang W., Carriquiry A., Nettleton D., and, Dekkers J. C. M., (2007) Pooling mRNA in microarray experiments and its effect on power. Bioinformatics 23, 1217-1224.
47. del Zoppo G. J., Levy D. E., Wasiewski W. W., Pancioli A. M., Demchuk A. M., Trammel J., Demaerschalk B. M., Kaste M., Albers G. W., and, Ringelstein E. B., (2009) Hyperfibrinogenemia and functional outcome from acute ischemic stroke. Stroke 40, 1687-1691.